Global Cancer Monoclonal Antibodies Market

The clinical oncology next generation sequencing market consists of sales of devices and equipment used in clinical oncology next generation sequencing and related services by entities (organizations, sole traders and partnerships) that manufacture clinical oncology next generation sequencing equipment. Next generation sequencing is a process used to determine the sequence of nucleotides in a section of DNA and is used for oncology research. Only goods and services traded between entities or sold to end consumers are included. The clinical oncology next generation sequencing market covered in this report is segmented by technology into ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real time sequencing, ligation sequencing, reversible dye termination sequencing, nano-pore sequencing. The global clinical oncology next generation sequencing market is also segmented by application into screening, companion diagnostics, other diagnostics and by end user into hospital laboratories, clinical research organizations, diagnostic laboratories. The global clinical oncology next generation sequencing market is expected to grow from $0.44 billion in 2020 to $0.56 billion in 2021 at a compound annual growth rate (CAGR) of 27.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global clinical oncology next generation sequencing market is expected to reach $1.05 billion in 2025 at a CAGR of 17%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the clinical oncology next generation sequencing market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for clinical oncology next generation sequencing market. High costs associated with the clinical oncology next generation sequencing is a major issue faced by patients across the globe. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In low-income countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low average life expectancy. According to an article published in July 2019 by Genetics in Medicine, the genome sequencing costs per cancer case is around £6,841, and costs per rare disease are around £7,050, and this cost is due to consumables that are the most expensive components in the sequencing process, and the equipment cost for rare cancer disease is higher when compared with normal cancer equipment, thus restraining the growth of the market. Companies in the clinical oncology next generation sequencing are increasingly investing in automation of workflow to increase precision and reduce the sample to sample variability. For instance, Agilent automation solutions have developed an automation system that allows increasing the number of reactions that can perform in parallel, and reducing the amount of sample processing time, and increasing the number of samples which can be processed while reducing the variability amount from sample to sample. Companies such as Sophia Genetics are also investing in data-driven medicine that looks into automating DNA sequencing to better diagnose and treat patients. In August 2019, Agilent Technologies acquired BioTek Instruments for $1.2 billion. The acquisition is expected to grow the presence and expertise of Agilent in cell analysis and strengthens the position of Agilent in the large and growing immune-oncology and immunotherapy areas. BioTek Instruments is a Vermont-based company that sells scientific instruments and associated software. Major players in the market global clinical oncology next generation sequencing market are Thermo Fisher Scientific (Qiagen), Oxford Nanopore Technologies, QIAGEN, Myriad Genetics, Illumina, F. Hoffmann-La Roche, Perkin Elmer, Agilent Technologies, Pacific Bioscience, and Caris Life Sciences. The regions covered in this report the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the market global clinical oncology next generation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global clinical oncology next generation sequencing market is segmented - 1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing 2) By Application: Screening, Companion Diagnostics, Other Diagnostics 3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic laboratories

The cancer monoclonal antibodies market consists of sales of monoclonal antibodies used for the treatment of cancer and related services by entities (organizations, sole traders and partnerships) that produce monoclonal antibodies for cancer treatment. Monoclonal antibodies are highly specific molecules for cancer cells as they bind to the proteins on their surface and it activates an immune response. The market consists of revenue generated by cancer monoclonal antibodies companies manufacturing cancer monoclonal antibodies drugs. The cancer monoclonal antibodies market covered in this report is segmented by monoclonal antibody therapies into bevacizumab (avastin), rituximab (rituxan), trastuzumab (herceptin), cetuximab (erbitux), panitumumab (vectibix), others and by application into breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, others. The global cancer monoclonal antibodies market is expected to grow from $45.51 billion in 2020 to $49.77 billion in 2021 at a compound annual growth rate (CAGR) of 9.4%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer monoclonal antibodies market is expected to reach $69.96 billion in 2025 at a CAGR of 9%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibodies market. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the cancer monoclonal antibodies market. The high costs involved in the development of monoclonal antibodies with advanced techniques act as a major restrain for the market due to the complex production process, expensive biological and chemical materials, and clinical trials, as well as required safety, efficacy, and quality tests. Advanced equipment is required for the large-scale production of monoclonal antibodies that encompass multiple disulfide bonds and post-translational modifications, and this equipment is expensive. Clinical efficacy is usually achieved by injecting large amounts of monoclonal antibodies into the system, which means that large quantities are required to be produced for each treatment, thus increasing the cost. According to The American Journal of Managed Care, the annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states. Thus, the high development costs in using these advanced techniques will restrain market growth. Companies in the cancer monoclonal antibodies market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over recent years. For instance, in September 2020, AbbVie and I-Mab entered into a strategic partnership for the development and commercialization of lemzoparlimab (also known as TJC4), which is a monoclonal antibody drug used to treat multiple cancers. In September 2019, IRBM announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center. The agreement will focus on the development of therapeutic monoclonal antibodies for cancer. In March 2020, Gilead Sciences, a US-based biopharmaceutical company, announced its decision to acquire Forty Seven for $4.9 billion. This acquisition is expected to strengthen Gilead’s immuno-oncology R&D portfolio with the addition of Forty Seven’s investigational lead product candidate, magrolimab. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers. Forty Seven Inc. is a clinical-stage immuno-oncology company that develops therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University. Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co., and Spectrum Pharmaceuticals. The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cancer monoclonal antibodies market is segmented - 1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Others 2) By Application: Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others 3) By End User: Hospitals And Clinics, Research Laboratories, Pharmacies, Others

The cancer clinical decision tools market consists of sales of cancer decision support tools and related services. Cancer decision tools are designed to support the general practitioner's assessment of patients with potential cancer symptoms. The tools do not change the clinical judgment but give more information that is used to inform patient management decisions. The risk is measured based on reading coded information from the patient record including demographic data, medical history, and symptoms. The cancer clinical decision tools market covered in this report is segmented by type into risk assessment tool (RAT), Qcancer and by end-user into hospitals, clinics. The global cancer clinical decision tools market is expected to grow from $0.36 billion in 2020 to $0.39 billion in 2021 at a compound annual growth rate (CAGR) of 8.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer clinical decision tools market is expected to reach $0.55 billion in 2025 at a CAGR of 9%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer clinical decision tools market. According to the American Cancer Society, there were 1.7 million new cases and 0.6 cancer deaths in 2019 in the USA. The four most common types of cancers worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rates across the globe will increase the demand for cancer clinical decision tools to make treatment decisions faster, thereby contributing to the market growth. The breach of data and privacy of patients is a major challenge in the cancer clinical decision tools market. Hackers can get access to data centers through healthcare employee’s emails leading to a breach of patients' information privacy. For instance, in 2019, the Regional Cancer Care Association (RCCA) reported a data breach through phishing email attempts. Email phishing is a primary attack because it is not detectable by email security tools, out of 15 million patient records breached, 11.4 million records were caused by phishing attacks. The risk of the loss of data and privacy of patients harms the growth of the cancer clinical decision tools market. In January 2019, Qiagen, a Germany based provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research acquired N-of-One for an undisclosed amount. The acquisition of N-of-One will enable QIAGEN to significantly expand its decision-support solutions while offering a broader range of software, content and service-based solutions. It will also enable QIAGEN to expand its clinical bioinformatics capabilities in molecular oncology decision support. N-of-One, a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. Major players in the cancer clinical decision tools market are McKesson Corporation, Medical Information Technology Inc., Philips Healthcare, Siemens Healthineers, Elsevier B.V., Macmillan, and National Decision Support Company. The regions covered in the cancer clinical decision tools market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer clinical decision tools market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cancer clinical decision tools market is segmented - 1) By Type: Risk Assessment Tool (RAT), Qcancer 2) By End-User: Hospital, Clinics

The cancer biologics market consists of sales of cancer biologics. Cancer biologic drugs are the products that are produced from living organisms or contain components of a living organisms. Biologic drugs include a wide variety of products which are derived from human, animal or microorganisms by using biotechnology. The cancer biologics market covered in this report is segmented by type into monoclonal antibodies, vaccines, cell and gene therapy, others. The cancer biologics market is also segmented by application into hospitals, clinics, others. The global cancer biologics market is expected to grow from $66.12 billion in 2020 to $70.69 billion in 2021 at a compound annual growth rate (CAGR) of 6.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer biologics market is expected to reach $93.34 billion in 2025 at a CAGR of 7.2%. Rising prevalence of chronic diseases is one of the major factors driving the cancer biologics market growth. Chronic disorders are the diseases which persists over a long period of time and hinder the health of people with disabilities and cancer is one of the common chronic diseases. The most common cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. According to World Health Organization (WHO), by 2020 chronic diseases would account for 75% of deaths globally. The cancer biologics market is being restrained by the adverse effects associated with the use of cancer biologics. Biologic drugs are administered by injection or infusion as they are proteins which are quickly digested and inactivated if given by mouth so they can cause injection site reactions or infusion reactions. Moreover, the adverse effects of the biologics vary from common side effects such as allergic reactions and diarrhoea to serious adverse effects such as low blood pressure, hepatitis and hypothyroidism. For instance, according to a study conducted by NCBI, biological agents are essential additions to chemotherapy for GI malignancies that leads to enhanced survival response rates but these additions also bring some unique adverse reactions to the patients. Companies in the cancer biologics market are developing predictive biomarkers which help the physicians to decide the treatments for their patients by utilizing physiological biomarkers for predicting the performance. Predictive biomarkers study tumor growth in patients by analyzing the major etiological factors as the cancer etiology differs from patient to patient. Moreover, these biomarkers not only aid in the early detection of cancer but also help in deciding the cost-effective treatment regimens, especially for the biologics based on gene therapy. According to FDA approval process of new cancer treatment and biological products, the application for the approval should include all relevant data available from clinical studies, including negative results as well as positive findings. Data can come from pharmaceutical company sponsored clinical trials intended to test the safety and effectiveness of a new use of a product, or from a number of alternative sources. In May 2019, Evotec SE, drug discovery and development solutions provider acquired Just Biotherapeutics, Inc. for $90 million. The acquisition will help Evotec's business to grow into offering the biologics into the therapeutic areas such as oncology. Just Biotherapeutics, a US-based unique technology company that integrates highly synergistic scientific expertise and ML driven technologies for development and manufacturing of biologics at highest standards. Major players in the cancer biologics market are AbbVie Inc., Hoffman-La Roche, GlaxoSmithKline, Eli Lilly and Company, and Amgen Inc. The regions covered in the cancer biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cancer biologics market is segmented - 1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Others 2) By Application: Hospitals, Clinics, Others

The cancer diagnostics market consists of sales of cancer diagnostic devices and equipment. Cancer diagnostic equipment is used to identify biomarkers, proteins and symptoms in order to detect a cancerous tumor in the patient. Cancer diagnostics market is segmented into companion diagnostics and molecular diagnostics. The cancer diagnostics market covered in this report is segmented by products into companion diagnostics, molecular diagnostics. The cancer diagnostics market is also segmented by end-user into cancer research institutes, diagnostic laboratories, hospitals, others; by method into biopsy, endoscopy, tumor biomarker tests, imaging; by application into cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, others. The global cancer diagnostics market is expected to grow from $156.27 billion in 2020 to $170.21 billion in 2021 at a compound annual growth rate (CAGR) of 8.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer diagnostics market is expected to reach $239.23 billion in 2025 at a CAGR of 8.9%. A high prevalence rate of various types of cancers is a major driver of the cancer diagnostics market. This is because the increasing incidences of various types of cancers is leading to a greater number of people opting for diagnosis and treatment. In addition, according to the World Health Organization (WHO), cancer was the second-leading cause of death worldwide. The National Cancer Institute (NCI) has estimated the number of new cancer cases per year to reach 23.6 million by 2030. Product recall is one of the major restraints for the cancer diagnostics market. Product recall is a process of retrieving all faulty and defective products that have been sold or are available in the market. When a company recalls a product from the market, it takes up the cost of fixing the defective product and replacing it. This cost of replacement of cancer diagnostics devices can be very high for manufacturers, which ultimately restricts the growth of the market. For example, Siemens Healthcare Diagnostics had to recall its IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay as it was not meeting the required high-dose hook effect expectation. An IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay can be used as an aid in the detection of prostate cancer along with digital rectal examination (DRE) in men aged 50 years or older. AI-based cancer detection system is an emerging trend in the cancer diagnostics market. AI helps in improving the accuracy of image detection in diagnostic processes such as breast cancer and lung cancer diagnostics, by detecting the cancers in early stages. AI also reduces the instances of false positives in lung cancer screening, thus, improving the lung cancer detection accuracy. For instance, researchers at the Naval Medical Center San Diego and Google's AI research division Google AI, developed a reliable solution comprised of cancer-detecting algorithms used for autonomous evaluation of lymph node biopsies. This AI solution improved the accuracy of metastatic breast cancer detection to 99%. The cancer diagnostics market is regulated by the FDA which imposes restrictions on cancer diagnostic devices such as magnetic resonance imaging (MRI) and nuclear magnetic resonance spectroscopy (NMR). The FDA categorizes these devices into class II category, as they have a moderate risk associated with usage. Class II devices are bounded by device specific regulations which include performance standards, premarket data requirements, post market surveillance and labelling requirements associated with their usage. For instance, the labelling of such devices is required to have a list of contraindications, adverse reactions, precautions, warnings and other instructions before being released in the market. Hence, regulations such as these would keep a check on manufacturers of cancer diagnostics devices. Major players in the cancer diagnostics market are Abbott, Becton Dickinson and Company, Hoffmann-La Roche Ltd, GE Healthcare Ltd., and Thermo Fisher Scientific. The regions covered in the cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cancer diagnostics market is segmented - 1) By Products: Companion Diagnostics, Molecular Diagnostics 2) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Others 3) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging 4) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Others

The blood and blood components market consist of sales of blood and blood component. The market involves collection of donor's blood and segregating it into required components for the purpose of therapy. The blood and blood components market covered in this report is segmented by product into whole blood, blood components. The blood and blood components market is also segmented by end-users into hospitals, ambulatory surgical centers, others; by application into anemia, trauma & surgery, cancer treatment, bleeding disorders; by blood components into red blood cells, platelets, plasma, white blood cells. The global blood and blood components market is expected to grow from $36.47 billion in 2020 to $38.43 billion in 2021 at a compound annual growth rate (CAGR) of 5.4%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The blood and blood components market is expected to reach $45.18 billion in 2025 at a CAGR of 4.1%. The blood and blood components market is being driven by increasing incidence of trauma and road accidents. Sometimes, because of traumas such as hemorrhage, the volume of blood is reduced to a very low level and cannot be replaced fast enough by the body. Also, road accidents cause excessive blood loss from the body that has to be restored immediately. At times, the blood itself lacks a few components as in the case of hemophilia. All these conditions demand transfusion of blood and blood components into the patient's body. The growing prevalence of diseases and increasing numbers of road accidents and traumas are increasing the demand for blood and thus driving the market. According to a report by Globenewswire, in 2019, around 20,000 men suffer from Hemophilia in the US alone. Also, as per US NIH data, in 2019, traumatic injury was found to be the foremost reason of mortality among 1-40 years old people. The blood and blood components market is restrained by the growing risk of developing or transferring an infection while the blood is transmitted to the patients. The growing possibilities of developing any transfusion transmitted infection (TTI) is imposing a restriction on the growth of the market. The fear of transfusion of diseases from the donor to the recipient, forces many customers to avoid using donated blood, thus hampering the growth of the blood and blood components market. The most common viral agents that can be transmitted through blood transfusion are Human Immunodeficiency Virus (HIV), hepatitis viruses, West Nile Virus (WNV), Human T-cell Lymphotrophic Viruses (HTLVs). The most prominent trend that has been witnessed in the blood and blood components market is the growing number of collaborations between the players involved in the market. Companies are adopting partnerships and collaborations in order to expand their reach, increase customer base and generate awareness in the market. For example, the American Red Cross collaborated with HealthStream with an aim of introducing new program for healthcare organizations. Similarly, the BloodCenter of Wisconsin collaborated with SysLogic Inc., to study how the RFID technology can be used to enhance safety of the patient while collecting and transfusing blood products. The blood and blood components market in European Union is governed by Directive 2002/98/EC of the EU regulations. The regulatory body engages itself in providing guidelines and setting standards for quality and safety of collection, testing, processing, storage, and distribution of blood and blood components. These guidelines ensure greater quality and safety of whole blood and its components to prevent transmission of diseases and also highlight necessary measures for their collection and distribution. In March 2019, Grifols SA, Barcelona-based company acquired a 26% stake in Shanghai RAAS Products Co., Ltd. for $1.9 billion. As per the agreement, Grifols agreed to share its technological know-how and engineering services with Shanghai RAAS. The acquisition was undertaken to manufacture, commercialize and develop plasma products and transfusion diagnostic solutions in China. Shanghai RAAS Products Co., Ltd., a China-based company that is primarily engaged in the research and development, manufacture and distribution of blood products. Major players in the blood and blood components market are American Red Cross, Australian Red Cross Blood Service, Abbott Laboratories, Blood Centers of America, and Becton, Dickinson & Co. The regions covered in the blood and blood components market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the blood and blood components market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global blood and blood components market is segmented - 1) By Product: Whole Blood, Blood Components 2) By End-Users: Hospitals, Ambulatory Surgical Centers, Others 3) By Application: Anemia, Trauma & Surgery, Cancer Treatment, Bleeding Disorders 4) By Blood Components: Red Blood Cells, Platelets, Plasma, White Blood Cells

The hematology analyzers and reagents market consist of sales of hematology analyzers and reagents. Hematology analyzers provide complete blood count (CBC) with a three-part differential white blood cell (WBC) count and can detect small cell populations to diagnose rare blood conditions, measure cell morphology. The hematology analyzers and reagents market covered in this report is segmented by product into hematology analysers, hemostasis analysers, plasma protein analysers, hemoglobin analysers, erythrocyte sedimentation rate analyser, coagulation analyser, flow cytometers, slide stainers, differential counters, hematology stains. The hematology analyzers and reagents market is also segmented by applications into anemias, blood cancers, hemorrhagic conditions, infection related conditions, immune system related conditions, others and by end user into specialized research institutes, hospitals, specialized diagnostic centers, others. The global hematology analyzers and reagents market is expected to grow from $3.93 billion in 2020 to $4.31 billion in 2021 at a compound annual growth rate (CAGR) of 9.7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The hematology analyzers and reagents market is expected to reach $5.69 billion in 2025 at a CAGR of 7.2%. The rising number of blood donations globally is driving the hematology analyzers and reagents market as hematology analyzers are used to test and screen blood in blood banks. Blood collected from donors through blood donation camps or bloodmobiles is sent to blood banks where hematology analyzers are used to screen and test the blood. These screening tests determine the blood type, analyze the blood plasma and detect infectious diseases. Blood banks are witnessing a huge outflow of blood to hospitals and other end-users and inflow of blood from blood donations on a daily basis. According to the WHO, there was an increase of 7.8 million blood donations from voluntary unpaid donors from 2013 to 2018. As the number of people donating blood increases, the demand for hematology analyzers and reagents increases, thereby driving market growth. Recalls of defective hematology analyzers is acting as a restraint on the hematology analyzers and reagents market. A product recall is done by the manufacturer or developer of the product as a precautionary measure when safety issues or defects are discovered that can endanger the consumer. A faulty hematology analyzer may provide wrong results and may lead to misdiagnosis, affecting consumer confidence in the analyzers. Regulatory authorities caution healthcare professionals to be aware of the potential for inaccurate diagnostic results with these analyzers and to take appropriate actions including the use of alternative diagnostic testing or confirming analyzer results with manual scanning or estimate of cell counts. For instance, Beckman Coulter Life Sciences recalled its DxH800 and DxH600 and DxH 900 hematology analyzers due to the risk of inaccurate results. Such kind of product recalls not only pose serious safety risk to the public but can also cause significant financial and reputational damage to the companies concerned. Hematology analyzers manufacturers are increasingly investing in the research and development of analyzers with microfluidics technology that use low volumes of sample and reagents. Microfluidics deal with the flow of liquids inside channels as small as a few micrometers. Low reagent consumption by hematology analyzers with microfluidics technology helps reduce operating costs significantly. For instance, the HA5 hematology system from BioSystems is based on microfluidics technology and uses approximately 75% less reagents compared to normal hematology analyzers. Also, the respons®3H and respons®5H hematology systems by DiaSys use microfluidics technology and consume 70% less reagents. In January 2019, Luminex Corporation acquired flow cytometry portfolio of EMD MilliporeSigma for $75 million. EMD Millipore Corporation supplies tools for biotechnology, life science and pharmaceutical industries. It was founded in 1954 and headquartered in Massachusetts, USA. Major players in the hematology analyzers and reagents market are Abbott, Bio-Rad Laboratories, Horiba, Siemens, and Sysmex. The regions covered in the hematology analyzers and reagents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hematology analyzers and reagents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global hematology analyzers and reagents market is segmented - 1) By Product: Hematology Analysers, Hemostasis Analysers, Plasma Protein Analysers, Hemoglobin Analysers, Erythrocyte Sedimentation Rate Analyser, Coagulation Analyser, Flow Cytometers, Slide Stainers, Differential Counters, Hematology Stains 2) By Applications: Anemias, Blood Cancers, Hemorrhagic Conditions, Infection Related Conditions, Immune System Related Conditions, Others 3) By End User: Specialized Research Institutes, Hospitals, Specialized Diagnostic Centers, Others

The drugs for hormonal replacement therapy market consists of sales of drugs for hormonal replacement therapy and related services. The drugs for hormonal replacement therapy are used to treat patients with growth hormone deficiency caused due to conditions such as dwarfism or menopause (a condition which describes changes a woman goes through when her menstruating cycle stops). The drugs for hormonal replacement therapy help to replace low level hormones from the body, maintain growth hormone deficiency and prevent women from vaginal dryness, mood swings, weakening of bones and others. The market covered in the drugs for hormonal replacement therapy market report is segmented by therapy type into estrogen replacement therapy, human growth hormone (HGH) replacement therapy, thyroid replacement therapy, testosterone replacement therapy; by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies; by application into hypothyroidism, male hypogonadism, growth hormone deficiency, menopause, others; by route of administration into oral, parental, others. The global drugs for hormonal replacement therapy market is expected to grow from $14.76 billion in 2020 to $14.88 billion in 2021 at a compound annual growth rate (CAGR) of 0.8%. The slow growth is mainly due to defering treatments that led to fall in the demand for drugs. The drugs for hormonal replacement therapy market is expected to reach $16.77 billion in 2025 at a CAGR of 3%. Increasing population of aging and postmenopausal women is driving the drugs for hormonal replacement therapy market growth. Hormonal replacement therapy drugs such as Estrogen, Progestin and others are used to treat medical conditions caused due to menopausal conditions. According to a report by The Indian Menopause Society, New Delhi, in India there are 65 million women over the menopausal age affected with menopausal symptoms. According to European Menopause and Andropause Society (EMAS) report, women aged over 60 are expected to reach over 1 billion by 2050. In South Korea, the female population is expected to exceed male population by 2060, out of which 59.6% of female population is expected to suffer from postmenopausal symptoms. Thus, growing women population suffering from menopausal symptoms and aging population drives the market for hormonal replacement therapy drugs market. Increasing occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder growth of drugs for hormonal replacement therapy market. The side effects include vagina dryness, irregular heartbeat, breast swelling, osteoporosis (weakening of bones) and other effects when women undergo hormonal replacement therapy. High dosage of drugs for hormonal replacement therapy may cause rapid heartbeat, bloating (a build-up of gas in the stomach and intestines), nausea, indigestion, vaginal bleeding, blood clots, heart attack, breast cancer and others. According to an online study, decrease in the intake of drugs for combined hormone therapy showed a decrease in breast cancer cases by 126,000 and cardiovascular disease cases by 76,000. Thus, the increasing side effects of drugs hinders the growth of drugs for hormonal replacement therapy. Companies in the industry are increasingly developing of drugs for hormonal replacement therapy with better safety profiles and novel drug delivery mechanisms. The drug delivery mechanisms include transdermal estrogen, varginal estrogen and others. Transdermal estrogen drug delivery is in the form of estradiol transdermal gel, patch, and spray that are used to treat symptoms of menopause, vaginal dryness, itching, burning and others occur due to low estrogen levels. Varginal estrogen in the form of cream, vaginal ring, vaginal tablets are used to get the hormone estrogen into the system. For instance, Novo Nordisk, a multinational pharmaceutical company provides novel drug delivery mechanisms and low dose drugs for hormonal replacement therapy (HRT) to cater to the rising demand of patient needs. Some of the brands offering of novel drugs include Climara, Divigel, Elestrin, Esclim, Estraderm, Estrasorb, EstroGel, Evamist, Oesclim, Rhoxal-Estradiol Derm 50, Vivelle 100 Mcg, Estradot Transdermal Therapeutic System and others. Department Of Health And Human Services of Food And Drug Administration (FDA), a federal agency, is a regulatory body monitoring, controlling and regulating the drugs for hormonal replacement therapy market. In April 2018, FDA's Department Of Health And Human Services has revised the requirements of specific hormone-containing drug products for human use. These hormones include estrogens, progestins, androgens, anabolic steroids, adrenal corticosteroids, and synthetic analogs. The purpose of the revisal of existing regulations by FDA is to establish effectiveness and ensure safety for any over-the-counter drug use of these ingredients. Major players in the drugs for hormonal replacement therapy market are Novartis AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, and Eli Lilly and Company. The regions covered in the drugs for hormonal replacement therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drugs for hormonal replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global drugs for hormonal replacement therapy market is segmented - 1) By Therapy Type: Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Application: Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause, Others 4) By Route of Administration: Oral, Parental, Others